[A20-36] Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2020
Commission awarded on 31.03.2020 by the Federal Joint Committee (G-BA).
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Clear advantages in overall survival and symptomatic progression, disadvantages in some side effects; overall: indication of considerable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-20||Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A19-09||Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|